Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Other Operating Assets
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Other Operating Assets of $2.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-05-07
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $2.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-06-30 was -$11.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-03-31 was -$13.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2023 was $231.00K, a 49.34% decline from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2022 was $456.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2021 was -$125.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.00K derived: sum of 2 quarters · filed 2025-11-06 | -$24.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$24.00K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | -$13.00K 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$12.00K derived: sum of 2 quarters · filed 2025-11-06 | -$216.00K 10-Q · filed 2025-11-06 | $5.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$217.00K 10-Q · filed 2025-08-07 | $4.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$204.00K 10-Q · filed 2025-05-08 | $17.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $231.00K 10-K · filed 2024-02-22 | ||
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $456.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $456.00K 10-Q · filed 2023-11-09 | $456.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $456.00K 10-Q · filed 2023-08-10 | $456.00K derived: sum of 3 quarters · filed 2024-02-22 | $456.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $456.00K 10-Q · filed 2023-05-11 | $456.00K derived: sum of 2 quarters · filed 2024-02-22 | $456.00K derived: sum of 3 quarters · filed 2024-02-22 | $433.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | -$23.00K derived: sum of 3 quarters · filed 2024-02-22 | -$125.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$23.00K derived: sum of 2 quarters · filed 2022-11-10 | -$125.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$125.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$102.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |